Review
Nucleoside transport and its significance for anticancer drug resistance

https://doi.org/10.1016/S1368-7646(98)80047-2Get rights and content

Abstract

This article discusses the role of nucleoside transport processes in the cytotoxicity of clinically important anticancer nucleosides. This article summarizes recent advances in the molecular biology of nucleoside transport proteins, review the current state of knowledge of the transportability of therapeutically useful anticancer nucleosides, and provide an overview of the role of nucleoside transport deficiency as a mechanism of resistance to nucleoside cytotoxicity are summarized. Several strategies for utilization of nucleoside transport processes to improve the therapeutic index of anticancer therapies, including the use of nucleoside-transport inhibitors to modulate toxicity of both nucleoside and non-nucleoside antimetabolite drugs are also presented.

References (127)

  • VijayalakshmiD et al.

    Sodium-dependent nucleoside transport in mouse intestinal epithelial cells. Two transport systems with differing substrate specificities

    J Biol Chem

    (1988)
  • HuangQQ et al.

    Functional expression of Na(+)-dependent nucleoside transport systems of rat intestine in isolated oocytes of Xenopus laevis. Demonstration that rat jejunum expresses the purine-selective system N1 (cif) and a second, novel system N3 having broad specificity for purine and pyrimidine nucleosides

    J Biol Chem

    (1993)
  • BeltJA et al.

    Nucleoside transport in normal and neoplastic cells

    Adv Enzyme Regul

    (1993)
  • FlanaganSA et al.

    Characterization of a novel Na+-dependent, guanosine-specific, nitrobenzylthioinosine-sensitive transporter in acute promyelocytic leukemia cells

    J Biol Chem

    (1997)
  • AronowB et al.

    Thymidine incorporation in nucleoside transport-deficient lymphoma cells

    J Biol Chem

    (1985)
  • CassCE et al.

    Absence of binding sites for the transport inhibitor nitrobenzylthioinosine on nucleoside transport-deficient mouse lymphoma cells

    Biochim Biophys Acta

    (1981)
  • CohenA et al.

    Characterization of a mutant mouse lymphoma cell with deficient transport of purine and pyrimidine nucleosides

    J Biol Chem

    (1979)
  • UllmanB et al.

    Genetic analysis of 2′,3′-dideoxycytidine incorporation into cultured human T lymphoblasts

    J Biol Chem

    (1988)
  • EllisonRR et al.

    Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults

    Blood

    (1968)
  • JamiesonGP et al.

    Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells

    Leuk Res

    (1990)
  • WileyJS et al.

    Cytosine arabinoside transport by human leukaemic cells

    Eur J Cancer Clin Oncol

    (1983)
  • GatiWP et al.

    Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein

    Blood

    (1997)
  • WeickJK et al.

    A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study

    Blood

    (1996)
  • BishopJF et al.

    A randomized study of high-dose cytarabine in induction in acute myeloid leukemia

    Blood

    (1996)
  • VijayalakshmiD et al.

    L1210/B23.I cells express equilibrative, inhibitor-sensitive nucleoside transport activity and lack two parental nucleoside transport activities

    J Biol Chem

    (1992)
  • CrawfordCR et al.

    Nucleoside transport in L1210 murine leukemia cells. Evidence for three transporters

    J Biol Chem

    (1990)
  • CurtinNJ et al.

    Modulation of dipyridamole action by alpha I acid glycoprotein. Reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamole

    Biochem Pharmacol

    (1989)
  • JansenWJ et al.

    The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumor xenografts

    Eur J Cancer

    (1995)
  • SmithCL et al.

    Nucleoside transport and proliferative rate in human thymocytes and lymphocytes

    Blood

    (1989)
  • AllayJA et al.

    Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors

    Blood

    (1997)
  • LowenbergB et al.

    Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-II, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group

    Blood

    (1997)
  • OhnoR et al.

    A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia

  • GriffithsM et al.

    Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs

    Nature Med

    (1997)
  • RitzelMWL et al.

    Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransporter (hCNTI)

    Am J Physiol

    (1997)
  • GriffithsM et al.

    Molecular cloning and characterization of anitrobenzylthioinosine- insensitive (ei) equilibrative nucleoside transporter from human placenta

    Biochem J

    (1997)
  • WangJ et al.

    Na+-dependent purine nucleoside transporter from human kidney: cloning and functional characterization

    Am J Physiol

    (1997)
  • RitzelMWL et al.

    Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine

    Mol Membr Biol

    (1998)
  • CassCE

    Nucleoside transport

  • BuolamwiniJK

    Nucleoside transport inhibitors: structure-activity relationships and potential therapeutic applications

    Curr Med Chem

    (1997)
  • WangJ et al.

    Functional and molecular characteristics of Na(+)-dependent nucleoside transporters

    Pharm Res

    (1997)
  • CheM et al.

    Ectonucleotidases, purine nucleoside transporter, and function of the bile canalicular plasma membrane of the hepatocyte

    FASEB J

    (1997)
  • YaoSY et al.

    Transport of adenosine by recombinant purine- and pyrimidine-selective sodium/nucleoside cotransporters from rat jejunum expressed in Xenopus laevis oocytes

    Mol Pharm

    (1996)
  • RooversKI et al.

    Characterization of equilibrative and concentrative Na+-dependent (cif) nucleoside transport in acute promyelocytic leukemia NB4 cells

    J Cell Physiol

    (1996)
  • BeltJA et al.

    Sodium-dependent nucleoside transport inhuman myeloid leukemic cell lines and freshly isolated myeloblasts

  • PatersonAR et al.

    Inhibitor-sensitive, sodium-linked transport of nucleoside analogs in leukemia cells from patients

  • ChesonBD

    Miscellaneous chemotherapeutic agents

  • MackeyJR et al.

    Functional nucleoside transporters are required for gemcitabine influx and cytotoxicity in cancer cell lines

    Cancer Res

    (1998)
  • UllmanB

    Dideoxycytidine metabolism in wild type and mutant CEM cells deficient in nucleoside transport or deoxycytidine kinase

    Adv Exp Med Biol

    (1989)
  • HoffmanJ

    Murine erythroleukemia cells resistant to periodate-oxidized adenosine have lowered levels of nucleoside transporter

    Adv Exp Med Biol

    (1991)
  • SobreroAF et al.

    Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-2′-deoxyuridine

    Cancer Res

    (1985)

    • Cited by (143)

    • The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells

      2020, Biomedicine and Pharmacotherapy

    • Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial

      2017, The Lancet Gastroenterology and Hepatology
      Citation Excerpt :

      Moreover, a head-to-head comparison of trials assessing these two regimens is difficult, given differences in patient profiles and rates of second-line chemotherapy across participating countries.6,7 Gemcitabine is a hydrophilic prodrug that requires the presence of specialised integral membrane nucleoside transporter proteins to efficiently permeate into tumour cells.8 Among these, the major mediator of gemcitabine uptake into human cells is the hENT1 protein.

    • Chemotherapeutic intervention by inhibiting DNA polymerases

      2016, DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications: Second Edition

    • Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate

      2014, International Journal of Pharmaceutics

    • Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: Correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy

      2014, Journal of Urology
      Citation Excerpt :

      The results indicate that expression of these proteins was not related to pathological complete response after NAC. Our sample size to determine a difference was predicated on the assumption that a third of patients would be good risk and the remaining poor risk based on previous work,10,11 along with an expectation of a pT0 rate of approximately 38%. However, the pT0 rate was significantly lower, consistent with other reports in the literature of contemporary NAC series using gemcitabine based therapy.12–14

    • Overcoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma

      2024, Biomedicines
    View all citing articles on Scopus
    View full text
    Copyright © 1998 Published by Elsevier Ltd.